27.03.2017 • NewsElaine BurridgeWilliamsGeismar

Daelim Bids for Williams Geismar Plant

(c) George Clerk/Getty Images
(c) George Clerk/Getty Images

South Korea’s Daelim Industrial has joined the main bidding to acquire Williams Partners’ olefins plant in Geismar, Louisiana, USA, according to a report in the newspaper Korea Economic Daily. Williams announced last September that it would sell its majority 88.5% stake in the plant, or seek a long-term tolling agreement.

Daelim is said to have joined a “host of global chemical companies” to bid for the asset with the sale price expected to reach 2-3 trillion won ($1.8-2.7 billion). Quoting a source close to the bidding, the newspaper said: “If the final bidder attempts to acquire not only the ethane cracker but also pipelines for supply of natural gas, the acquisition price could rise up to more than 3 trillion won.

Last month, Williams said it expected final bids for the sale of the olefins facility late in the first quarter of 2017. In its fourth-quarter earnings 2016 release, the group said the sale was “positively progressing” and that it expects to raise more than $2 billion in after-tax proceeds from planned asset monetizations of Geismar and other select assets not core to our strategy. “We expect proceeds from these monetizations will be used for additional debt reduction and to fund capital and investment expenditures,” it added.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.